An updated patent review of isoflavones and isocoumarins (2018-2024) [0.03%]
异黄酮和异香豆素专利回顾更新(2018-2024)
Hidayat Hussain
Hidayat Hussain
Introduction: It is well established that isocoumarins and isoflavones exhibit intriguing biological effects. During the period 2018-2024 isocoumarins and isoflavones chemistry has attracted attention due to their biologi...
5'-ectonucleotidase (CD73) inhibitors: a patent review (2021-present) [0.03%]
5'-核苷酸外酶（CD73）抑制剂专利回顾（2021至今）
Zhaolin Wang,Anna Junker
Zhaolin Wang
Introduction: Adenosine-mediated immunosuppression is a major mechanism of tumor immune escape and is largely driven by ecto-5'-nucleotidase (CD73), which catalyzes the formation of extracellular adenosine and limits the ...
LSD1 inhibitors for anticancer therapy: an updated patent review (2022-2025) [0.03%]
抗癌治疗中的 LSD1 抑制剂专利回顾（2022-2025）
Zhoudong Zhang,Jiyu Li,Zitong Wang et al.
Zhoudong Zhang et al.
Introduction: Lysine-specific demethylase 1 (LSD1) is a key epigenetic enzyme relying on flavin adenine dinucleotide to regulate gene expression via histone H3 demethylation and non-histone substrate modification. Discove...
Patents involving monoamine oxidase (MAO): a comprehensive update (2022-2025) on its inhibitors and applications [0.03%]
涉及单胺氧化酶(MAO)的专利：其抑制剂和应用的全面更新(2022-2025)
Moataz A Shaldam,Simone Carradori,Marwa Balaha et al.
Moataz A Shaldam et al.
Introduction: Monoamine oxidases (MAOs) A and B are key enzymes for the oxidative deamination of monoamine neurotransmitters, including dopamine, serotonin, norepinephrine, and tyramine. Selective MAO-B inhibitors are cli...
Recent advances in factor XII(a) inhibitors: an updated patent landscape (2020-present) [0.03%]
最近的因子XII(a)抑制剂研究进展：2020年至今的专利布局更新
Dmitrii V Kalinin
Dmitrii V Kalinin
Introduction: Factor XII (FXII) is a liver-derived plasma zymogen that autoactivates on anionic surfaces to FXIIa, which drives the contact blood coagulation pathway, kallikrein-kinin signaling, fibrinolysis, and classica...
Protein tyrosine phosphatase 1B (PTP1B) inhibitors as potential anti-diabetes agents: updated patent review (2019-2023) [0.03%]
蛋白酪氨酸磷酸酶1B(PTP1B)抑制剂作为潜在的抗糖尿病药物：2019-2023年专利回顾更新
Rafia Ashfaq,Hidayat Hussain
Rafia Ashfaq
Introduction: Inhibition of protein tyrosine phosphatase 1B (PTP1B) is a key strategy for improving insulin sensitivity in various cells. This strategy is supported by human genetic data. PTP1B inhibitors are considered a...
Novel fatty acid amide hydrolase (FAAH) inhibitors: a patent review from 2015 to 2025 [0.03%]
2015-2025年脂肪酸酰胺水解酶(Fatty Acid Amide Hydrolase, FAAH)的新型抑制剂专利评述
Laura Landolfi,Margherita Brindisi,Valentina Onnis et al.
Laura Landolfi et al.
Introduction: Over the past decade, significant efforts have been made to develop and patent selective fatty acid amide hydrolase (FAAH) inhibitors with favorable pharmacokinetic and safety profiles to modulate pain, infl...
A patent review of galectin-1 and galectin-3 inhibitors and their potential therapeutic applications (2022-present): an update [0.03%]
2022年至今关于半乳糖凝集素-1和半乳糖凝集素-3抑制剂的专利回顾及其潜在治疗应用：更新版
Aaftaab Sethi,Mallika Alvala
Aaftaab Sethi
Introduction: Galectin-1 (Gal-1) & Galectin-3 (Gal-3) are carbohydrate-binding proteins implicated in diverse pathological processes. These galectins have emerged as key therapeutic targets, with significant presence in d...
A patent review of DNA polymerase theta (Polθ) targeted therapies (2019-2025) [0.03%]
2019年至2025年靶向DNA聚合酶θ(Polθ)的专利综述
Luyu Ma,Mingjin Luo,Hua Xiang et al.
Luyu Ma et al.
Introduction: DNA Polymerase theta (Polθ), a critical multifunctional DNA repair enzyme in the alternative non-homologous end joining (alt-NHEJ) pathway, has recently emerged as a new promising synthetic lethal target fo...
LAG-3 antagonists for cancer treatment: an updated patent review (2020-2025) [0.03%]
癌症治疗的LAG-3拮抗剂专利回顾（2020-2025）
Martín Pérez-Santos,Gerardo Landeta,Maricruz Anaya-Ruiz et al.
Martín Pérez-Santos et al.
Introduction: LAG-3 is a molecule overexpressed on the surface of CD4+ and CD8+ cells in the tumor microenvironment that prevents T-cell activation and production of IL-2 and IFN-γ. ...